PASSION CAN CURE ANYTHING!
WHY WE DO IT
The 2018 Nobel Prize in Medicine was awarded to two cancer immunotherapy researchers (J. Allison and T. Honjo), acknowledging the fact that checkpoint blockade immunotherapy is revolutionizing clinical oncology. However, only a subset of patients exhibit durable clinical responses and new technologies are needed to enable highly precise and effective immunotherapy in ALL cancer patients.
WHAT WE DO
We develop and apply next-generation mass spectrometry technologies to advance the field of cancer immunotherapy.
We aim to better understand the mechanisms of tumor response and resistance to checkpoint immunotherapy
We identify protein biomarkers of response and relapse to checkpoint immunotherapy
We identify new forms of tumor-specific neoantigens to design innovative cancer vaccines
We are co-founder of the Human Immuno-Peptidome Project (HIPP) and we develop the SysteMHC Atlas project to enable "Big Immuno-Peptidomic Data" research and management
HOW WE DO IT
We apply mass spectrometry-based proteomics, immunopeptidomics, computational mass spectrometry and bioinformatics approaches
We collaborate with researchers and clinical investigators
We build the dream team!